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Abstract
Introduction: This study aims to elucidate the prognosis and the effectiveness of current treatments for Japanese
patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).
Methods: Patients with newly diagnosed MPA and GPA were enrolled in a nationwide, prospective, inception
cohort study from 22 tertiary Japanese institutions, and treatment patterns and responses were evaluated for
24 months. Primary outcome measures were rates of remission (Birmingham Vasculitis Activity Score, 0) and
remission with low-dose glucocorticoids (GC) (prednisolone ≤ 10 mg) (GC remission).
Results: Of 156 enrolled patients, 78 MPA patients and 33 GPA patients were included. Concomitant cyclophosphamide
(CY) was used in 24 MPA (31 %) and 20 GPA (60 %) patients during the initial 3 weeks of treatment. After 6 months,
remission was achieved in 66 MPA (85 %) and 29 GPA (87 %) patients, while GC remission was obtained in only 31 MPA
(40 %) and 13 GPA (39 %) patients. During the 24-month period, 14 MPA patients and 2 GPA patients died; end stage
renal disease (ESRD) was noted in 13 MPA patients but no GPA patients. Patients with severe disease, according to the
European Vasculitis Study Group (EUVAS) classification, showed poorer ESRD-free and overall survival rates than those
with generalized disease (p < 0.0001). There were no differences in relapse-free survival rates between GPA and MPA,
among EUVAS-defined disease severity categories, and between anti-neutrophil cytoplasmic antibody subspecialties.
Conclusions: The majority of Japanese patients with MPA and GPA received treatment with high-dose GC and limited
CY use, and showed high remission and relapse-free survival rates but low GC remission rates in clinical practice.
Trial registration: University Hospital Medical Information Network Clinical Trials Registry UMIN000001648. Registered 28
February 2009.
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Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is characterized by blood vessel inflamma-
tion with few or no immune deposits and the presence of
ANCA positivity. Recently, the 2012 revised International
Chapel Hill Consensus Conference Nomenclature of
Vasculitides classified AAV into four clinically relevant
subsets: microscopic polyangiitis (MPA), granulomatosis
with polyangiitis (GPA), eosinophilic granulomatosis with
polyangiitis (EGPA), and renal-limited AAV (RLV), con-
sidered an organ-specific variant of MPA [1]. Watts et al.
[2] proposed an epidemiological classification algorithm
(the European Medicines Agency (EMEA) algorithm),
which classifies primary systemic vasculitis into EGPA,
GPA, MPA/RLV, and polyarteritis nodosa, with no
overlaps between the categories. Significant differences in
clinical characteristics and ANCA serology of AAV be-
tween European and Asian patients have been suggested
[3]. A European epidemiologic study showed a domin-
ance of GPA over MPA [4], while our prospective study
[5] and two retrospective studies from China [6] and Japan
[3] that applied the EMEA algorithm found perinuclear/
myeloperoxidase (MPO)-ANCA-positive MPA to be the
most common form of AAV in Asia.
The guidelines of the British Society of Rheumatology
(BSR) and the European League Against Rheumatism
(EULAR) recommended assessment for treatment with
high-dose glucocorticoids (GC) and concomitant cyclo-
phosphamide (CY) or rituximab as the first-line option
for all patients with newly diagnosed AAV, in principle
[7, 8]. These recommendations are based on several ran-
domized controlled trials (RCTs) enrolling more patients
with GPA than with MPA [9–11]. Since patients with
MPA were older and tended to exhibit higher levels of
creatinine than those with GPA in our cohort of
Japanese patients [5], these recommendations should be
applied to Asian patients with caution in terms of safety.
Recently, Ozaki et al. [12] have reported the treatment
effectiveness stratified by disease severity for Japanese
patients with MPO-ANCA-positive MPA in a pros-
pective observational study. However, differences in
treatment effectiveness between MPA and GPA patients
and across the spectrum of disease severity remain to be
clarified.
We have previously reported the demographic and
baseline clinical characteristics of Japanese patients with
AAV who were enrolled in a nationwide, prospective, in-
ception cohort study of Remission Induction Therapy in
Japanese patients with ANCA-associated Vasculitides
(RemIT-JAV). In the present study, we aimed to eluci-
date and compare treatment and its effectiveness in
terms of remission, survival, and relapse rates in clinical
practice in Japanese patients with MPA and GPA using
the RemIT-JAV cohort database.
Methods
Settings and patient population
Database
Details regarding the RemIT-JAV study protocol have
been reported previously [5]. Twenty-two tertiary care
institutions participated in this study and enrolled 156
consecutive patients with newly diagnosed AAV from
April 2009 to December 2010. The criteria for enrol-
ment included a diagnosis of AAV made by the site in-
vestigators that fulfilled the criteria for primary systemic
vasculitis proposed by the EMEA algorithm: symptoms
and signs characteristic of or compatible with a diagno-
sis of AAV or polyarteritis nodosa; at least one of histo-
logical proof of vasculitis, positive serology for ANCA,
specific investigations strongly suggestive of vasculitis
and/or granuloma, or eosinophilia; and no other diagnosis
to account for symptoms/signs [2]. “Specific investiga-
tions” included neurophysiological tests for mononeuritis
multiplex, conventional or magnetic resonance angiog-
raphy, and thoracic or neck magnetic resonance imaging/
computed tomography imaging, depending on the signs
and symptoms of the patients. The site investigators ex-
cluded patients with malignancy, infection, drug-induced
vasculitis, secondary vasculitis, other types of vasculitides,
vasculitis mimics, sarcoidosis, and other nonvasculitic
granulomatous disease. Of the 156 patients enrolled, 78,
33, and 14 were classified as MPA, GPA, and EGPA, re-
spectively. The present study included all patients with
MPA or GPA from the RemIT-JAV study, but not those
with EGPA. The RemIT-JAV study was conducted ac-
cording to the Declaration of Helsinki and the ethical guide-
lines for epidemiologic research in Japan. Written informed
consent was obtained from each participant, and the study
protocol was approved by the ethics committees at each
participating institution (refer to Acknowledgements). The
RemIT-JAV study was registered to the University Hospital
Medical Information Network Clinical Trials Registry
(UMIN000001648).
Data collection
Each patient’s baseline data included demographic in-
formation, comorbidities, laboratory data, Birmingham
Vasculitis Activity Score (BVAS), imaging data, and re-
spiratory function data. Patients were evaluated at 3, 6,
12, 18, and 24 months after diagnosis and at relapse, and
the following data were collected: vital status, BVAS,
laboratory data, treatments, and adverse events. Organ
involvement was defined according to BVAS system.
Disease severity was determined by the categorization
system developed by the European Vasculitis Study
Group (EUVAS) [13]. The Vascular Damage Index (VDI)
was also collected at 6, 12, and 24 months. Chest radiog-
raphy, thoracic computed tomography, arterial blood gas
analysis, and respiratory function data were collected at
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12 and 24 months in patients with pulmonary involve-
ment. Because the RemIT-JAV study was an observa-
tional study, a treatment protocol was not provided.
Selection and dosage of immunosuppressants, dosage of
GC, and concomitant usage of plasmapheresis were
determined at the discretion of the attending physi-
cians. Observation was completed in March 2013, and
the baseline characteristics have been described pre-
viously [5].
Site investigators filled out the electronic case report
forms for each patient and submitted them to the RemIT-
JAV data center at the Department of Medicine and
Clinical Science, Okayama University Graduate School
of Medicine, Dentistry and Pharmaceutical Sciences,
Okayama, Japan.
Primary and secondary outcomes
The primary effectiveness outcome of the present study
was the remission rate. We analyzed two types of remis-
sion in this study. The first type of remission was deter-
mined systematically by a BVAS of 0 on two occasions
at least 1 month apart according to EULAR recom-
mendations for conducting clinical studies and/or clin-
ical trials in systemic vasculitis [13]. The second type of
remission was defined as BVAS of 0 plus a daily pred-
nisolone (PSL) dose of ≤10 mg (designated as “GC
remission” hereafter). GCs other than PSL were con-
verted to an equivalent dose of PSL.
Secondary effectiveness outcomes included cumulative
overall end-stage renal disease (ESRD)-free and relapse-
free survival rates. ESRD was defined as dependence on
dialysis or an irreversible increase in serum creatinine
level of >5.6 mg/dl (500 μmol/l). Based on the aforemen-
tioned EULAR recommendations, relapse was defined as
the reoccurrence or new onset of disease activity attrib-
utable to active inflammation. Major relapse was defined
as a relapse with organ-threatening or life-threatening
disease activity, and other relapses were classified as
minor [13].
The safety outcome was the type and incidence of ser-
ious infections (SIs). Our definition of SIs was based on
an International Conference on Harmonisation report
[14]. Bacterial infections that required intravenous anti-
biotic administration and opportunistic infections were
regarded as SIs. The diagnosis of infection was based on
the attending physicians’ clinical diagnosis, using a com-
prehensive evaluation of physical findings, laboratory
data, and imaging data.
Statistical analysis
We used baseline and follow-up data at 3, 6, 12, 18, and
24 months from the patients with MPA and GPA en-
rolled in this study. The cumulative remission, overall
survival, ESRD-free survival, and relapse-free survival
rates were analyzed using the Kaplan–Meier method
and the log-rank test. p <0.05 was considered significant
for statistical analyses between two categories. When
comparing three or four categories, statistical sig-
nificance was determined by p <0.05/3 or p <0.05/4 by
Bonferroni correction to avoid multiplicity. When no pa-
tients in a group achieved an endpoint, the group was
excluded from the long-rank test. As such, the patients
with limited type disease, as defined by EUVAS
categorization [13], were excluded from the analysis of
survival and ESRD-free survival, and patients with early
systemic type disease were excluded from the analysis of
ESRD-free survival.
All statistical analyses were performed by a biostatisti-
cian using the Statistical Package of JMP for Windows




Of the 156 patients with AAV enrolled in the RemIT-
JAV study, 78 patients with MPA/RLV and 33 patients
with GPA were included in the present study. The mean
(median) observation periods were 559 (730) days in
MPA patients and 653 (730) days in GPA patients, re-
spectively. At 24 months, 52 patients with MPA and 28
patients with GPA remained in the cohort (Fig. 1).
Selected patient characteristics and treatment of these
patients are summarized in Table 1; details regarding pa-
tient characteristics have been described in our previous
report [5].
Treatment patterns
Changes in treatment over time in patients with MPA
and GPA are presented in Table 1 as observed data. The
mean initial daily PSL dose was 41 mg in MPA patients
and 40 mg in GPA patients. Concomitant CY was used
during the initial 3 weeks of remission induction therapy
in 24 of 78 (31 %) MPA patients and 20 of 33 (60 %)
GPA patients. One GPA patient and three MPA patients
were treated with plasma exchange. Hemodialysis was
implemented at any time point during the initial
3 months in 13 of 78 (14 %) MPA patients and 2 of 33
(6 %) GPA patients. At 3 months, the daily PSL dose
was tapered down to ≤15 mg in 29 of 67 (43 %) MPA
patients and 10 of 32 (31 %) GPA patients.
At 6 months, the mean daily PSL dose was 12 mg in
MPA patients and 13 mg in GPA patients, and 10 of 62
MPA patients (16 %) and 8 of 30 GPA patients (27 %)
were receiving concomitant azathioprine. Data regarding
treatment were not obtained in one patient with MPA.
The mean daily PSL dose decreased gradually thereafter
in both groups.
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Remission
No statistically significant differences in remission rates
were found between MPA and GPA patients (Fig. 2a). By
6 months, 66 of 78 MPA patients (85 %) and 29 of 33
GPA patients (87 %) achieved remission, as defined by
BVAS of 0 on two occasions at least 1 month apart.
However, only 31 of 78 MPA patients (40 %) and 13 of
33 GPA patients (39 %) satisfied the definition of GC re-
mission; that is, BVAS of 0 remission plus a daily PSL
dose of ≤10 mg.
When both patients with MPA and those with GPA
were classified into four different types (i.e. limited, early
systemic, generalized, and severe) according to the
EUVAS-defined disease severity, there were no signifi-
cant differences in remission rates across the spectrum
of disease severity (Fig. 2b). Remission and GC remission
were obtained by 6 months in four (100 %) and three
(75 %) of four patients with the limited type, in 18
(90 %) and 10 (50 %) of 20 patients with the early
systemic type, in 58 (89 %) and 24 (37 %) of 65 patients
with the generalized type, and in 15 (68 %) and 7 (32 %)
of 22 patients with the severe type, respectively.
No significant differences in remission and GC remis-
sion rates at 6 months were noted between MPO-
ANCA-positive and peroxidase-3 (PR3)-ANCA-positive
patients, or between patients with or without interstitial
lung disease (ILD).
Overall survival
Sixteen deaths were reported during the observation
period (14 MPA patients and two GPA patients). Causes
of death reported by site investigators were vasculitis
itself (five patients), infection (six patients), and other or
unknown (five patients: completely unknown in two pa-
tients, cardiac failure in one patient, intracerebral
hemorrhage in one patient, and hyperkalemia in one
patient). Of the five cases of death caused by vasculitis
itself, all patients were treated with GC without
Fig. 1 Flow chart of the enrolled patients. GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis
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concomitant CY and two patients were treated with
plasma exchange. Renal manifestations developed in all
five cases and ESRD developed in two of five cases. Lung
manifestations developed in four of five patients in-
cluding pulmonary hemorrhage and ILD in one case,
ILD in one case, pleuritis in one case, and pulmonary
infiltration in one case.
In terms of overall survival rates, MPA patients tended
to have a worse prognosis than GPA patients, although
the difference did not reach statistical significance
(Fig. 3a; p = 0.12). In the spectrum of EUVAS disease
severity, there were significant differences in overall
survival rates among the four different types (Fig. 3b;
p = 0.0003). Patients with severe disease, showing the
lowest survival rate of 56 % at 24 months, had a markedly
poorer prognosis, even compared with those with general-
ized type disease (p <0.0001).
On the other hand, significant differences in survival
rates were undetectable between MPO-ANCA-positive
and PR3-ANCA-positive patients (82 % versus 92 % at
month 24) or between patients with and without ILD
(87 % versus 83 % at month 24).
ESRD-free survival
Thirteen cases of ESRD developed during the observa-
tion period in MPA patients, but none occurred in GPA
patients. Hence, the ESRD-free survival rate of MPA pa-
tients was significantly lower than that of GPA patients,
decreasing to 81 % at 24 months (Fig. 4a; p = 0.012). In
the spectrum of EUVAS disease severity, there were sig-
nificant differences in ESRD-free survival rates (Fig. 4b;
p <0.0001). Patients with severe type disease showed the
lowest ESRD-free survival rate of 51 % at 24 months,
which was much lower than that of patients with gener-
alized type disease (p <0.0001).
MPO-ANCA-positive patients tended to have lower
ESRD-free survival rates than PR3-ANCA-positive pa-
tients (84 % versus 100 % at 24 months), although this
difference was not statistically significant. No significant
difference in ESRD-free survival rates was detectable be-
tween patients with and without ILD (90 % versus 85 %
at 24 months).
Relapse
Of the 98 patients who achieved remission by 6 months,
23 relapsed during the total observation period, includ-
ing 18 MPA and five GPA patients, with a mean dur-
ation for the remission period of 566 days. Of the 23
relapses, 11 were major relapses and 12 were minor.
There were no significant differences in relapse rates be-
tween MPA and GPA patients (Fig. 5a; 29 % versus 15 %
at month 18) or among patients with the four different
types of EUVAS disease severity (Fig. 5b) (0 %, 42 %,
21 %, and 28 % at month 18 for limited, early systemic,
Table 1 Patient characteristics and treatments
MPA GPA
(n = 78) (n = 33)
Age (years), mean ± SD 71 ± 10 64 ± 13
Sex (male:female) 35:43 12:21
Disease severity, n
Limited 0 4
Early systemic 15 5
General 47 18
Severe 16 6
MPO-ANCA, n (%) 76 (97) 18 (55)
PR3-ANCA, n (%) 2 (3) 15 (46)
Serum creatinine (mg/dl),
mean ± SD
2.46 ± 2.18 1.51 ± 1.32
BVAS, mean ± SD 18 ± 7 20 ± 7
Initial treatments (within 3 weeks)
Maximum daily dose of
PSL (mg/day), mean ± SD
41 ± 15 40 ± 15
mPSL pulse use, n (%) 34 (44) 13 (39)
Cyclophosphamide, n (%) 24 (31) 20 (60)
Oral:intravenous 3:21 7:13
Cumulative dose for 6 months (g),
mean ± SD
2.6 ± 2.8 4.3 ± 3.6
Methotrexate, n (%) 0 (0) 2 (6)
Azathioprine, n (%) 0 (0) 0 (0)
Treatments at 6 months
n = 62 n = 30
Minimum daily dose of PSL (mg/day),
mean ± SD
12 ± 5 13 ± 6
Cyclophosphamide, n 20 16
Methotrexate, n 0 3
Azathioprine, n 10 8
Treatments at 12 months
n = 56 n = 28
Minimum daily dose of PSL (mg/day),
mean ± SD
9 ± 5 9 ± 6
Cyclophosphamide, n 9 7
Methotrexate, n 0 4
Azathioprine, n 11 11
Treatments at 24 months
n = 52 n = 28
Minimum daily dose of PSL (mg/day),
mean ± SD
7 ± 5 6 ± 3
Cyclophosphamide, n 4 5
Methotrexate, n 0 4
Azathioprine, n 10 5
ANCA antineutrophil cytoplasmic antibody, BVAS Birmingham Vasculitis Activity
Score, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis,
MPO myeloperoxidase, mPSL methylprednisolone, PR3 proteinase 3,
PSL prednisolone, SD standard deviation
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generalized, and severe types, respectively). In addition,
there were no significant differences in relapse rates be-
tween MPO-ANCA-positive and PR3-ANCA-positive pa-
tients (25 % versus 21 % at month 18) or between patients
with or without ILD (34 % versus 18 % at month 18).
SI and VDI
During the 2-year follow-up period, 76 SIs were reported
in 46 patients (41.4 %). The number of SIs decreased
over time, from 43 in 27 patients in the first 6 months
to 20 in 18 patients in the second 6 months, nine in
seven patients in the third 6 months, and four in four
patients in the last 6 months of follow-up. The most fre-
quent site of SI was the respiratory system (41 events),
followed by skin and subcutaneous tissue (12 events).
Frequently reported types of opportunistic infections
were deep mycoses (14 events), cytomegalovirus infec-
tion (10 events), and herpes zoster (nine events).
The mean (standard deviation) total VDI score of
MPA patients and GPA patients were 1.95 (1.55) and
1.64 (1.57) at 12 months and 2.13 (1.56) and 2.11 (1.79)
at 24 months, respectively.
Fig. 2 Cumulative remission rates in MPA and GPA patients and among the four EUVAS-defined disease severity types. a Remission rates in MPA
and GPA patients. b Remission rates among patients with the four types of EUVAS disease severity. BVAS Birmingham Vasculitis Activity Score,
GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis
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Discussion
This is the first prospective cohort study comparing the
responses of current immunosuppressive therapy in
Japanese patients between the two major AAV diseases,
MPA and GPA, in clinical practice. In our cohort, the
patients had been enrolled from 22 tertiary care in-
stitutions in Japan. The majority was positive for MPO-
ANCA and diagnosed with MPA, which is in contrast
with AAV patients in western countries who are charac-
terized by a predominance of PR3-ANCA and GPA. In
addition, although the EULAR recommendations and
the BSR guidelines recommend the concomitant use of
CY as induction therapy for severe or generalized AAV
[7, 8], concomitant CY was used in only 31 % of MPA pa-
tients and 60 % of GPA patients during remission in-
duction, and these rates were apparently lower than
those reported in western observational studies (76–82 %)
[15–17]. In previous studies, CY was not frequently used
in Japan for patients with MPA/RLV, because these pa-
tients often present with progressive renal impairment at
advanced ages and are thereby considered at high risk for
severe infections [15, 18].
Fig. 3 Cumulative overall survival rates in MPA and GPA patients and among the four EUVAS-defined disease severity types. a Survival rates in
MPA and GPA patients. b Survival rates among patients with the four types of EUVAS disease severity. Cumulative survival rates at 24 months are
shown at the end of the survival curve for each group. GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis
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In this study, we found that remission rates (BVAS of
0 on two occasions at least 1 month apart) at 6 months
were 85 % for MPA and 87 % for GPA, whereas GC re-
mission rates (BVAS of 0 plus PSL of ≤10 mg/day) were
40 % for MPA and 39 % for GPA. In patients with gener-
alized or severe type diseases, remission rates at month
6 were 84 % for MPA and 83 % for GPA. Time to remis-
sion was similar between MPA and GPA patients, and
almost all enrolled patients achieved remission at least
once during the observation period. These results are
probably comparable with the results reported in RCTs
conducted in Europe [19, 20]. In the CYCAZAREM trial
[19], 155 patients with generalized GPA and MPA
received oral CY and PSL for at least 3 months, and
patients who achieved remission by 6 months were
assigned to treatment with azathioprine or oral CY. A
total of 144 of 155 patients (93 %) achieved remission
with a BVAS of 0 by 6 months. In the CYCLOPS trial
[20], where 149 patients with generalized GPA and MPA
received intravenous pulses of CY or oral CY for at least
Fig. 4 Cumulative ESRD-free survival in MPA and GPA patients and among the four EUVAS-defined disease severity types. a ESRD-free survival
rates in MPA and GPA patients. b ESRD-free survival rates among patients with the four types of EUVAS disease severity. Cumulative ESRD-free
survival rates at 24 months are shown at the end of the survival curve for each group. ESRD end-stage renal disease, GPA granulomatosis with
polyangiitis, MPA microscopic polyangiitis
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3 months, 131 patients (78.9 %) achieved remission by
9 months.
Fourteen of 78 MPA patients and two of 33 GPA pa-
tients died during the 24-month observation period. The
mortality rate of 14 % in our cohort appears to be
slightly higher than the rates found in the European
RCTs. For example, eight deaths in 155 patients (5 %)
within 18 months and 14 deaths in 149 patients (9 %)
within 18 months were reported in the CYCAZAREM
and CYCLOPS trials, respectively [19, 20]. This difference
may be partly attributable to the fact that the mean age at
the first presentation was higher in our cohort (71 years
for MPA and 64 years for GPA) and a higher proportion
of patients with EUVAS-defined severe type disease were
enrolled in our study (20 %). The latter possibility is sup-
ported by the high mortality (35 deaths in 137 patients;
26 %) demonstrated in the MEPEX trial that selectively in-
cluded severe type MPA and GPA patients. It is intriguing
that the MEPEX trial included more than twice as many
MPA patients as GPA patients, similar to our study. A
Fig. 5 Relapse-free survival in MPA and GPA patients and among the four EUVAS-defined disease severity types. a Relapse-free survival rates in MPA
and GPA patients. b Relapse-free survival rates among patients with the four types of EUVAS disease severity. GPA granulomatosis with polyangiitis,
MPA microscopic polyangiitis
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recent comparison of MPA patients between Japan and
Europe showed no difference in cumulative patient sur-
vival [12, 15]. Thus, these results suggest that MPA may
have a worse vital prognosis than GPA, at least in part due
to the effects of age at onset.
Further, a marked difference between patients with
MPA or GPA in our cohort was found in terms of renal
failure. During the observation period, 13 ESRDs occurred
in MPA patients, whereas no ESRDs were reported in
GPA patients, clearly indicating that ESRD-free survival is
much worse with MPA. In agreement with this finding, a
retrospective analysis of a large-scale AAV patient data-
base demonstrated that MPO-ANCA-positive patients
presented with worse renal function and higher levels of
proteinuria, probably due to advanced chronic damage
with a smoldering clinical course, than PR3-ANCA-
positive patients [21]. Hauer et al. [22] reported that the
glomerular filtration rate (GFR) at entry and predomin-
antly chronic renal lesions were potent predictors of the
GFR at 18 months in ANCA-associated glomerulo-
nephritis. In the present study, MPA patients had a lower
average estimated GFR than GPA patients (38 versus
52 ml/minute/1.73 m2). These data would explain the sig-
nificant difference in ESRD-free survival between MPA
and GPA patients in our cohort.
The relapse rate of 23 % in our cohort was similar to the
rate reported recently in China (32.7 %) [23] but was
lower than the rates reported previously in western coun-
tries (45–76 % at 6 months and 38 % at 1 year) [24, 25].
The higher relapse-free survival rates in our cohort and
the Chinese cohort may be related to the predominance of
MPO-ANCA positivity in Asian patients with AAV,
because MPO-ANCA-positive AAV patients relapse less
frequently than PR3-ANCA-positive patients [16]. There
is also a possibility that relatively slow tapering of GC
contributed to a higher relapse-free survival in this study.
Although the British clinical guideline recommends rapid
tapering of PSL to 15 mg/day after 3 months of treatment
[8], more than half of our patients were still taking
≥15 mg/day PSL at month 3. However, it is highly contro-
versial whether fast tapering of GC is associated with in-
creasing risk of relapse in AAV patients. While some
studies supported this notion [26, 27], it has recently been
demonstrated that GC therapy beyond 6 months is associ-
ated with a greater risk of infections, but not with a de-
creased risk of relapse [24]. The incidence of SIs in the
present study was notably higher than those in previous
observational studies from European countries [24, 28].
The high incidence of SIs may relate to this slow tapering
of GC. On the contrary, VDI scores were comparable with
previous RCTs [29].
Our study has several limitations. First, institutional
bias should be considered, because this study was per-
formed in university and referral hospitals in Japan.
Because the participating institutions enrolled all pa-
tients with newly diagnosed AAV, the selection bias in
each institute was low. Second, we could not perform
multistratified or multivariate analysis for outcomes be-
cause of the small sample size. In addition, we could not
perform sufficient comparisons between MPO-ANCA-
positive and PR3-ANCA-positive patient groups, be-
cause there are few numbers of PR3-ANCA-positive
patients in this cohort and the observational period was
short. This problem will be solved in the future by com-
bination with another large-scale cohort study of Japanese
patients with AAV that is currently ongoing. Third,
the 2-year observation period could be too short to
evaluate the relapse rates of the disease. Fourth, our effect-
iveness data may be affected by indication bias because
treatments were determined at the discretion of the at-
tending physicians. More sophisticated statistical methods
should be employed to overcome this bias with a larger
number of patients.
Conclusions
The majority of Japanese patients with MPA and GPA
received treatment with high-dose GC and limited CY
use, and showed high remission and relapse-free survival
rates but low GC remission rates in clinical practice.
Further studies are needed to optimize treatment for
Japanese patients with AAV, who exhibit different clin-
ical characteristics than patients in western countries in
terms of genetic backgrounds, disease categories, and
ANCA serology.
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